References
- Caraco, Y. 2004. Genes and the response to drugs. The New England Journal of Medicine 351 (27):2867–9.
- Eichebaum, M., N. Spannbrucker, B. Steincke, and et al. 1979. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. The European Journal of Clinical Pharmacology 16:183–7.
- Fukuoka, M., S. Yano, G. Giaccone, and et al. 2003. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. Journal of Clinical Oncology 21 (12):2237–46.
- Kallioniemi, A., O. P. Kallioniemi, D. Sudar, and et al. 1992. Comparative genomic hy-bridization for molecular cytogenetic analysis of solid tumors. Science 258 (5083):818–21.
- Mahgoab, A., J. R. Idle, L. G. Drig, and et al. 1977. Polymorphic hydroxylation of debriso-quine in man. Lancet 2:584–6.
- Maitournam, A., and R. Simon. 2005. On the efficiency of targeted clinical trials. Statistics in Medicine 24:329–39.
- Paez, J. G., P. A. Janne, J. C. Lee, and et al. 2004. EGFR mutations in lung cancer: corre-lation with clinical response to gefitinib therapy. Science 304 (5676):1497–500.